key: cord-0760195-a0wmj7h2 authors: Lee, Moon O.; Sivasankar, Shyam; Pokrajac, Nicholas; Smith, Cherrelle; Lumba‐Brown, Angela title: Emergency department treatment of asthma in children: A review date: 2020-08-21 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12224 sha: 8db758ba6290b09d668b7dad98b6ae1af7a68743 doc_id: 760195 cord_uid: a0wmj7h2 Asthma is the most common chronic illness in children, with >700,000 emergency department (ED) visits each year. Asthma is a respiratory disease characterized by a combination of airway inflammation, bronchoconstriction, bronchial hyperresponsiveness, and variable outflow obstruction, with clinical presentations ranging from mild to life‐threatening. Standardized ED treatment can improve patient outcomes, including fewer hospital admissions. Informed by the most recent guidelines, this review focuses on the optimal approach to diagnosis and treatment of children with acute asthma exacerbations who present to the ED. Asthma is the most common chronic illness in children, affecting >6 million children in the United States. 1 In 2014 to 2015, of all emergency department (ED) visits in the United States, 9.5% had an asthma diagnosis documented in the medical record; the largest proportion of these patients were children aged 5 to 17 years (13%). 2 Each year, asthma accounts for >700,000 ED visits by children and 2% to 5% of all pediatric hospitalizations. 3, 4 In this review, we provide an up-to-date overview of the ED diagnosis and treatment of children with acute asthma exacerbations. Optimal treatment in the ED can improve patient outcomes, including both reducing ED length of stay and hospital admission rates. [5] [6] [7] [8] The review focuses on ED treatment and reflects the literature and guideline recommendations through 2019. We begin with a brief discussion of the clinical presentation of asthma in children, the differential diagnoses, and the scoring tools available to aid in the assessment of severity. We Young children can be particularly difficult to diagnose with asthma because wheezing can be caused by a variety of etiologies, most commonly respiratory viral infections. Rather than formally diagnosing children with asthma, ED clinicians are tasked with determining when to initiate treatment for a possible or likely asthma exacerbation. ED clinicians must use a combination of history and physical exam findings to determine when to start treatment while looking for alternative diagnoses if patients are not improving. A hallmark of asthma is recurrent exacerbations. Characteristic features of exacerbations include wheezing, cough, shortness of breath, and chest tightness. Caretakers may report a worsening of symptoms at night and fatigue or poor sleep, especially in school-age children. Exacerbations are often triggered by respiratory infections, creating considerable overlap between symptoms of an isolated viral lower respiratory tract infections and asthma. Other common triggers include inhaled irritants such as tobacco smoke, exposure to environmental allergens, or changes in weather. 9 Wheezing is the most common physical finding associated with asthma and is included on almost all published scoring tools for the assessment of asthma in children. 10 Wheezing should not be used in isolation. Wheezing is notably absent in many severe exacerbations as a result of a lack of airflow. 11 Wheezing may also be caused or mimicked by other disease processes. Wheezing is a high-pitched, continuous noise that is most often expiratory. Wheezing should not be confused with stridor, which is also high pitched but primarily inspiratory, or stertor, which is more variable in pitch and respiratory phase and is primarily associated with nasal congestion and discharge. Wheezing has good reliability in controlled studies of children with asthma and pneumonia. 10, 12, 13 In clinical practice, however, the assessment of wheezing is likely to be less valid and reliable when using loudness and focality to determine severity. Physical examination should focus on a child's mental status and respiratory effort. Particular attention should be paid to a child's mental status-a fussy, crying child is more reassuring than a quiet, listless child, which should alert the clinician to the possibility of more severe disease. On examination, children may have increased work of breathing which manifests as nasal flaring, facial pallor, grunting, head bobbing, and retractions. The expiratory phase may be notably prolonged and is usually associated with intercostal retractions and wheezing. In contrast, prolonged inspiration and sternal retractions are physical examination findings more consistent with an upper airway obstruction and should not be confused with a severe asthma exacerbation. The differential diagnosis of acute asthma exacerbation is detailed in Table 1 . Asthma may be challenging to diagnose in children and assessing the severity of an acute exacerbation may be particularly difficult. Any child with a reported asthma history unresponsive to asthma therapy requires reconsideration of the diagnosis. 14 Despite being the gold standard to diagnose asthma, pulmonary function tests and incentive spirometry lack reproducibility in young children and are unreliable during acute illness. Pulmonary function tests are also impractical in the ED and should not be used during an acute exacerbation. 11, 15, 16 Clinical assessments of children with an asthma exacerbation may also be variable. 17 To standardize clinical diagnosis and deliver timely ED care, several pediatric asthma scoring tools have been developed ( For patients with mild asthma, first-line treatment is albuterol hydrofluroalkane-pressurized (HFA) and an oral steroid, for example, dexamethasone, and may also include inhaled ipratropium. Patients with moderate to severe asthma exacerbations will typically receive Table 3 . Albuterol is one of the two mainstays of acute asthma treatment. Albuterol is a long-acting β2 receptor agonist, producing bronchodilation through smooth muscle relaxation. Albuterol's onset of action is <5 minutes, and duration of action is 3 to 6 hours. The most common side effects with albuterol are vomiting, tremor, and tachycardia attributed primarily to peripheral vasodilatation. 34 Albuterol is most commonly administered via HFA metered dose devices. Most young children cannot create a seal around the mouthpiece of the HFA and will need a mask and spacer to improve medication delivery. Albuterol can also be administered via nebulization, but albuterol HFA with a spacer delivers an equivocal dose compared with nebulizers. 35 Albuterol HFA also results in shorter ED length of stay, fewer hospital admissions, and no differences in oxygen saturations. 36, 37 Albuterol HFA is also the preferred mode of administration for patients under airborne precautions, such as for severe acute respiratory syndrome coronavirus 2. In severe asthma exacerbations, the use of continuous, nebulized albuterol is recommended. 35 Ipratropium, a muscarinic receptor antagonist, also produces bronchodilation as well as decreasing mucous production. Ipratropium's onset of action is 15 to 30 minutes and the duration of action is 3 to 5 hours. 39 Common side effects of ipratropium are dry mouth, headache, and nasal congestion. Ipratropium is typically added to albuterol in moderate or severe exacerbations. The addition of ipratropium to albuterol has been associated with reduced hospital admission in pediatric patients with moderate and severe asthma exacerbations. 40 Early initiation of ipratropium in the ED has been shown to prevent hospital admission, but little benefit has been reported in continued use in the critical care or floor setting after admission. 41 Systemic steroids are the other mainstay of acute asthma therapy. Multiple studies have shown early steroid administration in the ED reduces hospitalization. 6, 42 Recent literature supports dexamethasone as the preferred systemic steroid. Dexamethasone is a long-acting steroid that can be given orally or intramuscularly. Dexamethasone's onset of action when given orally is 1 to 2 hours and 30 to 120 minutes after intramuscularly administration. The half-life is 2 to 9 hours, and commonly reported side effects include nausea, vomiting, restlessness, and fatigue. 43 A 2016 study reported that 1 dose of dexamethasone was not inferior compared with 3 days of prednisone in terms of hospital admission rate or unscheduled return visits to healthcare providers. 44 In a study comparing a 2-dose regimen of oral dexamethasone to a traditional 5-day course of prednisone, similar efficacy with increased compliance was reported. 40, 45 In a separate study, children with acute asthma treated with 1 dose of dexamethasone had a 36% relative risk reduction in 72-hour ED return rate compared with children treated with a 3-5-day course of oral prednisone. 46 Dexamethasone is also more cost-effective and tastes better, and patients are more likely to complete treatment when compared with prednisolone. 47, 48 The literature comparing single-dose dexamethasone to multiple doses of dexamethasone is limited. Most studies suggest single-dose versus a daily dose for 2 days. 49 More research is needed to determine if providing a second oral dose will aid in pediatric exacerbation relapses as well as more investigation of the effect of this regimen in the hospitalized pediatric patient. 47 Prospective randomized trials show no clinical difference between oral and intramuscular steroid administration. 50 Magnesium is a second-line therapy in children presenting with moderate to severe asthma exacerbation. Magnesium is administered intravenously, competing for calcium channels with resultant smooth muscle relaxation and bronchodilation. Magnesium also decreases histamine release from mast cells and produces an anti-inflammatory effect by decreasing super-oxide production by neutrophils. 53 Magnesium's onset of action is immediate and given over 15 to 60 minutes. 54 Magnesium is well tolerated and has few side effects. Hypotension, dry mouth, nausea, flushing, hyporeflexia, and respiratory depression are reported but rare. Magnesium should be considered in patients insufficiently responsive to first-line treatment or for those with more severe presentations on arrival. In a 2016 Cochrane review of 5 randomized, placebocontrolled studies, children treated with intravenous magnesium were 68% less likely to be admitted to the hospital. There were insufficient data to evaluate the effects of magnesium administration on secondary outcomes, including ED treatment durations, ICU admission rates, hospital lengths of stay, and adverse events. 55 There is no conclusive evidence on the impact of inhaled versus intravenous magnesium. 56,57 Epinephrine and terbutaline are adjunctive therapies for patients with severe exacerbations who fail to improve after first-line treatment and magnesium. These patients will also typically be candidates for admission to the pediatric ICU, and concern for respiratory failure may be high. Epinephrine is both an α-agonist and β-agonist and induces smooth muscle relaxation as a result of systemic β-agonist effects and can be administered intramuscularly, subcutaneously, intravenously, or through nebulization. Epinephrine is typically administered intramuscularly in the ED because of more rapid availability and ease of administration, although the literature is mixed on improved efficacy of intravenous β-agonists. 58 Onset of action is 5 to 10 minutes if subcutaneous and immediate when given intravenously. The duration of action is <5 minutes intravenously. Most common side effects are anxiety, tremors, agitation, and sweating. Terbutaline is pure β-agonist and is an option for hypertensive patients who may not tolerate epinephrine. Subcutaneous dosing is only for children older than 12 years of age. Side effects of terbutaline include tachycardia, arrhythmias, hypokalemia, and rarely myocardial ischemia. 59 Ketamine is an N-methyl-D-aspartate receptor antagonist that has dissociative, amnestic, and analgesic properties. Ketamine has been shown to promote bronchodilation and prevent bronchospasm. 60, 61 Children with severe asthma in the ED who received a 2-hour ketamine infusion did not have improvement in respiratory rate, oxygen saturation, hospital admission rate, or need for mechanical ventilation when compared with normal saline. 62 However, ketamine has been shown to increase pulmonary compliance in mechanically ventilated patients. 63 Helium-oxygen mixture (heliox) is a potential adjunct for severe asthma exacerbations refractory to first-line and other adjuncts, in particular in patients at risk for respiratory failure. Heliox's potential benefit is indirect-it enhances the delivery of other inhaled treatments through its lower gas density by decreasing flow resistance, lowering viscosity, and increasing laminar flow. Heliox is available in concentrations of 80% helium/20% oxygen and 70% helium/30% oxygen. If the patient requires >40% oxygen, the potential beneficial effect is diminished. Ideally heliox should be started early in the patient's presentation. [64] [65] [66] Heliox has limited use past the first 24 hours of disease and in patients with hypoxia. 67, 68 The literature on heliox in children is limited to case reports or case studies and has shown conflicting results. One study demonstrated no significant improvement in the recovery of pulmonary function in children treated with heliox. 69 However, a 2014 meta-analysis examining 113 children found that the use of heliox in delivering continuous albuterol therapy was associated with a significant improvement in peak expiratory flow. 70 High-flow nasal cannula (HFNC) provides heated and humidified gas at a rate greater than typical inspiratory flow and is well tolerated by most patients. In addition, HFNC reduces anatomic dead space and potentially provides some degree of positive end-expiratory pressure. 71 The degree of positive end-expiratory pressure provided by HFNC is not as consistent as that provided by NIPPV. 72 HFNC is primarily used to treat respiratory distress/failure with bronchiolitis, and the literature on HFNC in asthma is limited. One A 2016 Cochrane review evaluated 2 randomized controlled trials that investigated the efficacy of BiPAP in children presenting with asthma exacerbations. Both studies report that BiPAP improves respiratory rate, accessory muscle use, and dyspnea as compared with standard therapy, but the effect on overall outcomes are unclear. 74 Despite NIPPV use, 7% of patients will progress to require mechanical ventilation. 75 Endotracheal intubation and mechanical ventilation may be indicated rarely for severe asthma, but the decision should not be taken lightly. Avoiding intubation is the primary goal of the other treatments for severe asthma. Patients who are candidates for intubation are already at risk for complications, including respiratory and cardiac arrest, and intubation only increases that risk. The apnea associated with medication-assisted approaches to intubation inevitably worsens hypercarbia and respiratory acidosis. The reported rate of complications of endotracheal intubation is as high as 26%, including hypotension, pneumothorax, subcutaneous emphysema, and cardiac arrest. 76, 77 Reported mortality after intubation is as high as 8%. 78 Worsening hypercarbia after the initiation of treatment is ominous, but hypercarbia in itself does not necessitate intubation. With aggressive therapy, intubation can be avoided. 79 Criteria used to consider endotracheal intubation include poor response to maximum therapy, hypercarbia (pCO2 > 50 mmHg), severe hypoxemia (PO2 < 60 mmHg), worse mental status, impending respiratory arrest indicated by respiratory depression or bradycardia, worse metabolic acidosis, and cardiopulmonary arrest. 76 Before the start of intubation attempts, asthma therapy should be maximized and a clear plan in place for cardiac arrest, with code doses of epinephrine and the defibrillator prepared. Ketamine is associated with bronchodilating properties and is a good choice for induction. As noted, the decision to use a paralytic medication specifically should be made with extreme caution and likely in consultation with critical care. As patients with severe asthma exacerbations will be intolerant of the resultant apnea; respiratory acidosis will worsen, maybe critically and irreversibly. If a paralytic medication is given, succinylcholine and rocuronium have rapid onset and are effective. 79 The patient should be oxygenated as well as possible before intubation. Cardiac arrest will often be preceded by worsening of hypoxemia and bradycardia, and loss of pulses may be subtle in a patient already in extremis. The care environment should therefore be as quiet as possible, with clear roles and responsibilities and anticipation of deterioration. Methylxanthines, such as aminophylline and theophylline, were historically used for acute asthma exacerbations. In recent years, the National Asthma Education and Prevention Program Expert Panel recommended against the use of methylxanthines for treatment of hospitalized children with status asthmaticus. 35 However, there has been some literature to suggest that there may be an indication for theophylline in the hospitalized pediatric ICU asthmatic patient. 82 Leukotriene-modifying agents, such as montelukast, are not indicated in the treatment of an acute asthma exacerbation in the ED, although they are often used as adjunct therapies for maintenance in the outpatient setting in addition to an inhaled corticosteroid. 83 The efficacy of inhaled nitric oxide in severe asthma exacerbations is unknown. The ED disposition of a child with an asthma exacerbation is dependent on his or her projected clinical stability and response to treatment. The aforementioned asthma severity scores may aid in prognostication of the need for hospital admission ( 87 When evaluated individually, providing comprehensive education resulted in a 6% to 7% reduction in readmission rates at 3 months. Bundling of measures further reduced readmission rates. Similar studies report mixed results, suggesting that a follow-up phone call may reduce ED revisits after hospitalization. 88, 89 In studies of caregivers of children with asthma, 90% believed that instruction regarding follow-up appointments, medications, reasons to seek medical care, and education in general were important aspects of the discharge process, preferably with live demonstration. 89, 90 Factors associated with an increased risk of return ED visits within the year include younger age, lower socioeconomic and educational status, and chronic obstructive pulmonary disease. 91 In addition, previous critical care admission for asthma increased a child's risk for readmission for an asthma exacerbation. 92 Consideration must be given to social determinants of health, as these may play a critical role in both effective treatment of individual patients and in eliminating disparities in care. Interventions supporting asthma education and counseling should address a spectrum of contextual and psychosocial factors that may not be included in historical or more traditional materials. 93, 94 Examples include inner-city dwelling, exposure to air pollution, presence of pests, stress in the home, low income and other limitations affecting access to care should be considered prior to discharge. Physician counseling, coordination with primary care from the ED, and social work consult from the ED visit may support a transition to outpatient care. Perhaps most important, effectively addressing the social determinants of health will almost certainly require multidisciplinary, institution-level commitments to initiatives that partner with community members and both government and nongovernmental groups. Asthma exacerbation in children is a common presentation in the ED often requiring escalation of care and hospital admission. Clinical scoring tools are important ED adjuncts to guide treatment, prognosticate disposition, and inform admission. Albuterol, ipratropium, and dexamethasone are the mainstays of acute treatment of severe acute asthma exacerbations in children. All 3 agents have been shown to prevent hospitalization and improve other short-term outcomes. More severe asthma exacerbations should be treated with magnesium. Endotracheal intubation should be approached with extreme caution given the high mortality rate and complications. The authors have no conflicts of interest to disclose. Moon O. Lee, Cherrelle Smith, Nicholas Pokrajac, Shyam Sivasankar, and Angela Lumba-Brown have made substantial contributions to National surveillance of asthma: United States QuickStats: Percentage of all emergency department (ED) visits made by patients with asthma, by sex and age group -National hospital ambulatory medical care survey, United States Status of childhood asthma in the United States Children's emergency department use for asthma Improving pediatric asthma outcomes in a community emergency department Early administration of systemic corticosteroids reduces hospital admission rates for children with moderate and severe asthma exacerbation Clinical pathway improves pediatrics asthma management in the emergency department and reduces admissions Standardized Asthma Admission Criteria Reduce Length of Stay in a Pediatric Emergency Department International consensus on (ICON) pediatric asthma Systematic review: Insufficient validation of clinical scores for the assessment of acute dyspnoea in wheezing children Noninvasive testing of lung function and inflammation in pediatric patients with acute asthma exacerbations Clinical scores for dyspnoea severity in children: a prospective validation study. Latzin P Reliability of examination findings in suspected community-acquired pneumonia Utility of portable spirometry in a pediatric emergency department in children with acute exacerbation of asthma Spirometry and PRAM severity score changes during pediatric acute asthma exacerbation treatment in a pediatric emergency department Large observer variation of clinical assessment of dyspnoeic wheezing children Direct concurrent comparison of multiple pediatric acute asthma scoring instruments Performance of a novel clinical score, the Pediatric Asthma Severity Score (PASS), in the evaluation of acute asthma The Preschool Respiratory Assessment Measure (PRAM): A responsive index of acute asthma severity Development and internal validation of a pediatric acute asthma prediction rule for hospitalization Improved outcomes for hospitalized asthmatic children using a clinical pathway Development of a clinical asthma score for use in hospitalized children between 1 and 5 years of age Prospective evaluation of two clinical scores for acute asthma in children 18 Months to 7 years of age: two pediatric asthma clinical scores PRAM score as predictor of pediatric asthma hospitalization Improving guideline-based care of acute asthma in a pediatric emergency department Implementation and improvement of pediatric asthma guideline improves hospital-based care Admission predictability of children with acute asthma Initial asthma severity assessment tools as predictors of hospitalization Pediatric asthma severity scores distinguish suitable inpatient level of care for children admitted for status asthmaticus Pediatric asthma severity score is associated with critical care interventions Asthma Clinical Pathway-Emergency Children's Hospital of Philadelphia 119018?searchUrl=%2Flco%2Faction% 2Fsearch%3Bjsessionid%3DBBC74EE0BA9900D24228006F35D20 BA6%3Forigin%3Dapi%26t%3Dglobalid%26q%3D5577%26nq% 3Dtrue Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma β-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis Association of various weight-based doses of continuous albuterol on hospital length of stay Lexicomp Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma Adjunct therapies for refractory status asthmaticus in children Early emergency department treatment of acute asthma with systemic corticosteroids ?searchUrl=%2Flco%2Faction% 2Fsearch%3Forigin%3Dapi&t%3Dglobalid&q%3D388152&nq% 3Dtrue#admp. Accessed A randomized trial of single-dose oral dexamethasone versus multidose prednisolone for acute exacerbations of asthma in children who attend the emergency department Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial Single-dose oral dexamethasone is effective in preventing relapse after acute asthma exacerbations Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations? A cost-effectiveness analysis of dexamethasone versus prednisone in pediatric acute asthma exacerbations: a cost-effectiveness analysis of dexamethasone for acute asthma Dexamethasone for acute asthma exacerbations in children: a meta-analysis Randomized trial of singledose intramuscular dexamethasone compared with prednisolone for children with acute asthma A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy Lexicomp Intravenous magnesium sulfate for treating children with acute asthma in the emergency department Intravenous magnesium therapy for moderate to severe pediatric asthma: Results of a randomized, placebo-controlled trial Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma Addition of intravenous beta 2 -agonists to inhaled beta 2 -agonists for acute asthma. Cochrane Database Syst Rev Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit Effects of ketamine on isolated human bronchial preparations Mechanism of the positive inotropic effect of ketamine in isolated ferret ventricular papillary muscle The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial Heliox for non-intubated acute asthma patients Heliox administration in the pediatric intensive care unit: an evidence-based review: Pediatr Crit Care Med Evaluation and treatment of critical asthma syndrome in children Use of helium-oxygen mixtures in the treatment of acute asthmaa Heliox-driven β2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis Nasal high flow in management of children with status asthmaticus: a retrospective observational study Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database Syst Rev Non-invasive ventilation in pediatric status asthmaticus: A prospective observational study Management of acute asthma in the pediatric patient: an evidence-based review Mortality in patients hospitalized for asthma exacerbations in the United States Acute severe asthma Mechanical ventilation for children with status asthmaticus Efficacy, results, and complications of mechanical ventilation in children with status asthmaticus Pressure-controlled ventilation in children with severe status asthmaticus Gas exchange response to intravenous aminophylline in patients with a severe exacerbation of asthma Role of leukotriene inhibitors in the treatment of childhood asthma. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie 7 Development of a pediatric asthma predictive index for hospitalization Discharging asthma patients on 3-hour β-agonist treatments: a quality improvement project Level of asthma controller therapy before admission to the hospital Impact of discharge components on readmission rates for children hospitalized with asthma Enhancing postdischarge asthma care by using pharmacy claims and telephone follow-up Parents support teach-back, demonstration, and a postdischarge phone call to augment discharge education Effective discharge communication in the emergency department Risk factors for return to the emergency department for asthma: a population-based study Time to asthma-related readmission in children admitted to the ICU for asthma Social determinants: taking the social context of asthma seriously Community organization to reduce the need for acute care for asthma among African American children in low-income neighborhoods: the neighborhood asthma coalition Emergency department treatment of asthma in children: A review conception and design, acquisition of data, or analysis and interpretation of data and have been involved in drafting the manuscript and revising it critically for important intellectual content, giving final approval of the version to be published.